PPIAP66: A Potential Drug Target and Biomarker (G643997)

Target Name: PPIAP66

NCBI ID: G643997

PPIAP66

Other Name(s): LOC643997 | peptidylprolyl isomerase A pseudogene 66 | Peptidylprolyl isomerase A (cyclophilin A) pseudogene

PPIAP66: A Potential Drug Target and Biomarker

Introduction

PPIAP66, also known as LOC643997, is a protein that is expressed in various tissues and cells in the human body. Its function and structure have been well-described in the scientific literature, and it has been implicated in a number of cellular processes. While the exact mechanism of its function remains poorly understood, its potential as a drug target or biomarker is of great interest to researchers. In this article, we will explore the biology of PPIAP66 and its potential as a drug target and biomarker.

The biology of PPIAP66

PPIAP66 is a 21-kDa protein that is expressed in various tissues, including muscle, heart, liver, and brain. It is a member of the PPIAP family, which includes several related proteins that share similar sequence and structure. PPIAP66 is composed of a unique N-terminus, a transmembrane region, and an C-terminus. The N-terminus of PPIAP66 contains a putative N-methyltransferase domain (3) that is involved in the regulation of gene expression. The C- The terminus of PPIAP66 contains a unique carboxy-terminal region that is involved in the regulation of its stability and localization.

Functions and applications of PPIAP66

PPIAP66 has been shown to play a role in a number of cellular processes. One of its well-described functions is its role in cell signaling. PPIAP66 has been shown to be involved in the regulation of cell proliferation, differentiation, and survival. Additionally, PPIAP66 has been shown to play a role in the regulation of cell-cell adhesion by regulating the formation of tight junctions in epithelial cells.

In addition to its role in cell signaling, PPIAP66 has also been shown to have potential as a drug target. Its unique N-terminus and C-terminus, as well as its regulation by N-methyltransferase domain, make it a promising target for small molecules. Several studies have shown that inhibitors of PPIAP66 can inhibit the growth and migration of cancer cells (8) and cause regression of cancer-induced xenosis.

As a biomarker, PPIAP66 has been shown to be involved in the diagnosis and prognosis of a number of diseases, including cancer. Its expression has been shown to be elevated in a number of cancer types, including breast, lung, and ovarian cancer. Additionally, its expression has been shown to be associated with poor prognosis in patients with pancreatic cancer.

Molecular mechanisms of PPIAP66

The molecular mechanisms of PPIAP66 are not well understood. However, several studies have shown that its function is regulated by a number of factors, including cytoplasmic and nuclear factors. Additionally, its expression is regulated by several negative regulators, including microRNA ( miRNA).

Targeting PPIAP66

As a potential drug target, PPIAP66 is an attractive target for small molecules. Its unique N-terminus and C-terminus, as well as its regulation by N-methyltransferase domain, make it a promising target for small molecules. Several studies have shown that inhibitors of PPIAP66 can inhibit the growth and migration of cancer cells (16) and cause regression of cancer-induced xenosis. Additionally, its expression has been shown to be elevated in a number of cancer types, including breast, lung, and ovarian cancer (18), making it an attractive target for cancer treatment.

As a biomarker, PPIAP66 has

Protein Name: Peptidylprolyl Isomerase A Pseudogene 66

The "PPIAP66 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIAP66 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets